Literature DB >> 11979453

Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis.

Jan-Inge Henter1.   

Abstract

Familial hemophagocytic lymphohistiocytosis (FHL) is, without treatment, an invariably fatal disease of infancy and early childhood characterized by fever, hepatosplenomegaly, pancytopenia, and a widespread accumulation of T-lymphocytes and macrophages. During recent years, the diagnosis and the survival as well as the understanding of the disease have improved dramatically. Recent studies suggest that FHL is caused by impaired lymphocyte-mediated cytotoxicity and defective triggering of apoptosis, and that the symptoms are mediated by a pro-inflammatory hypercytokinemia. Moreover, specific genetic alterations, mutations in the perforin gene, have been revealed in FHL patients. Perforin, which normally is secreted from cytotoxic T-lymphocytes and natural killer (NK) cells upon conjugation between effector and target cells, is able to insert into the membrane of the target cell. It there polymerizes to form a cell death-inducing pore through which toxic granzymes may enter the cell and trigger apoptosis. The establishment of perforin deficiency as a cause of the rapidly fatal disease FHL has demonstrated the essential role of perforin in human immune homeostasis. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11979453     DOI: 10.1002/mpo.1340

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  17 in total

1.  Perforin is a critical physiologic regulator of T-cell activation.

Authors:  Jennifer E Lykens; Catherine E Terrell; Erin E Zoller; Kimberly Risma; Michael B Jordan
Journal:  Blood       Date:  2011-05-23       Impact factor: 22.113

2.  Correspondence: cytomegalovirus complicating inflammatory bowel disease: useful remarks.

Authors:  Antonio Cascio; Chiara Laria; Filippo Ricciardi; Giovanni Pellicanò; Walter Fries
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11

3.  Cerebrospinal fluid involvement in a case of visceral leishmaniasis associated with hemophagocytic lymphohistiocytosis.

Authors:  Mahmoud Fathalla; Javad Hashim; Hussein Alkindy; Yasser Wali
Journal:  Sultan Qaboos Univ Med J       Date:  2007-12

4.  Loss of intrahepatic bile ducts: an important feature of familial hemophagocytic lymphohistiocytosis.

Authors:  Klaus Kapelari; Martin Fruehwirth; Andreas Heitger; Alfred Königsrainer; Raimund Margreiter; Burkhard Simma; Felix Albert Offner
Journal:  Virchows Arch       Date:  2005-05-20       Impact factor: 4.064

5.  Occurrence of haemophagocytic lymphohistiocytosis at less than 1 year of age: analysis of 96 patients.

Authors:  Shinsaku Imashuku; Ikuyo Ueda; Tomoko Teramura; Kanako Mori; Akira Morimoto; Masahiro Sako; Eiichi Ishii
Journal:  Eur J Pediatr       Date:  2005-02-25       Impact factor: 3.183

6.  Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality.

Authors:  Tiffany F Lin; Laura L Ferlic-Stark; Carl E Allen; Claudia A Kozinetz; Kenneth L McClain
Journal:  Pediatr Blood Cancer       Date:  2011-01       Impact factor: 3.167

7.  A novel perforin gene mutation in a Japanese family with hemophagocytic lymphohistiocytosis.

Authors:  Ikuyo Ueda; Urara Kohdera; Shigeyoshi Hibi; Tohru Inaba; Ken Yamamoto; Tohru Sugimoto; Akira Morimoto; Eiichi Ishii; Shinsaku Imashuku
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

8.  Macrophage activation syndrome in juvenile rheumatoid arthritis successfully treated with cyclosporine A: a case report.

Authors:  Chan-Ran You; Hae-Rim Kim; Chong-Hyeon Yoon; Sang-Heon Lee; Sung-Hwan Park; Ho-Youn Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

9.  Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients.

Authors:  Yenan T Bryceson; Eva Rudd; Chengyun Zheng; Josefine Edner; Daoxin Ma; Stephanie M Wood; Anne Grete Bechensteen; Jaap J Boelens; Tiraje Celkan; Roula A Farah; Kjell Hultenby; Jacek Winiarski; Paul A Roche; Magnus Nordenskjöld; Jan-Inge Henter; Eric O Long; Hans-Gustaf Ljunggren
Journal:  Blood       Date:  2007-05-24       Impact factor: 22.113

10.  Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?

Authors:  Demet Demirkol; Dincer Yildizdas; Benan Bayrakci; Bulent Karapinar; Tanil Kendirli; Tolga F Koroglu; Oguz Dursun; Nilgün Erkek; Hakan Gedik; Agop Citak; Selman Kesici; Metin Karabocuoglu; Joseph A Carcillo
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.